Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.~* Written informed consent obtained from the subject prior to performing of any study specific procedure.~* A male or female between, and including, 18 and 55 years of age at the time of enrolment.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Available to participate for the duration of the study.~* Female subjects of non-childbearing potential may be enrolled in the study.~  - Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test at enrolment, and~ * has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series and/or malaria challenge.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines during the period starting 30 days before the first dose of study vaccines (Day -29 to Day 0), or planned use during the study period.~* Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.~* Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone ≥ 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.~* Administration of long-acting immune-modifying drugs at any time during the study period.~* Chronic use of antibiotics with antimalarial effects.~* Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting seven days before the first dose.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.~* Seropositive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).~* Documented HIV-positive subject.~* Previous vaccination against malaria.~* History of malaria chemoprophylaxis within 60 days prior to vaccination.~* Any history of malaria (for the vaccine groups).~* Planned travel to malaria endemic areas during the study period.~* History of splenectomy.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Family history of congenital or hereditary immunodeficiency.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.~* History of anaphylaxis post-vaccination.~* Hypersensitivity to latex.~* History of any reaction or hypersensitivity likely to be exacerbated by chloroquine.~* History of psoriasis and porphyria, which may be exacerbated after chloroquine treatment.~* Current use of medications known to cause drug reactions to chloroquine.~* History of severe reactions to mosquito bites.~* Major congenital defects.~* Serious chronic illness.~* History of any neurological disorders or seizures.~* Acute disease and/or fever at the time of enrolment. Fever is defined as temperature ≥ 37.5°C/99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C/100.4°F for rectal route.~  - Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~* Any abnormal baseline laboratory screening tests: alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, hemoglobin, platelet count, total white blood cells (WBC), out of normal range as defined in the protocol.~* Evidence of increased cardiovascular disease risk, moderate or high, according to the National health and nutrition examination survey I criteria.~* Hepatomegaly, right upper quadrant abdominal pain or tenderness.~* Personal history of autoimmune disease.~* Administration of immunoglobulins and/or any blood products during the period starting three months before the first dose of study vaccine or planned administration during the study period.~* Pregnant or lactating female.~* History of chronic alcohol consumption and/or drug abuse.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.~* History of blood donation within 56 days preceding enrolment.~* Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- AduFx Group (Type: ACTIVE_COMPARATOR): Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and Month 1 and 1/5th of RTS,S/AS01B full dose at Month 7, and underwent sporozoite challenge.
- 2PedFx Group (Type: EXPERIMENTAL): Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E double dose at Month 0 and Month 1, and 1/5th of double dose RTS,S/AS01E at Month 7, and underwent sporozoite challenge.
- PedFx Group (Type: EXPERIMENTAL): Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E full dose at Month 0 and Month 1, and 1/5th of RTS,S/AS01E full dose at Month 7, and underwent sporozoite challenge.
- Adu2Fx Group (Type: EXPERIMENTAL): Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose at Month 1 and Month 7, and underwent sporozoite challenge.
- Adu1Fx Group (Type: ACTIVE_COMPARATOR): Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose administered at Month 7, and underwent sporozoite challenge.
- Control Group (Type: OTHER): Healthy subjects, between, and including, 18 and 55 years of age, who did not receive any immunization but underwent sporozoite challenge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete